life scienc tool diagnost unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
organ improv
beat academ surg us/eu fund pharma
steadi upsid smaller hope bigger buy-back
absorb base eros provis tax reform pt
base eros tax impact pressur bull case quarter stronger
top line margin expand ex-fx/mix debat event
though balanc higher tax rate risk potenti
larger share repurchas deliv repurchas program goe
higher vs trend rel base off-shore cash
access roughli line believ expect
call ultim base eros provis tax reform see pars
benefit howev oner water dilig
suggest like uk ireland rate effect go higher drive tax
rate higher rel includ upward
pressur stock comp account absorb upsid capit
deploy left wait clariti like path
capit deploy littl urgenc commentari
continu emphas intern invest repurchas
what mean tool group much asid valid
recent public manag commentari instruct
trend consist posit wat organ growth hold well
stabl vs trail qr trend spite tough comp surprisingli big
quarter academ exhibit drove result commentari
academ channel nih data see preview stack posit
alongsid stronger signal appli bioprocess academ
trend notabl saw evid
strong pre-announce see beat hurrican impact
drag line expect
detail top line decomposit pharma like remain
growth conservat outlook sustain europ
china lower visibl point said confirm us
market strong finish year custom seemingli hold back
spend earlier year political/pr polici uncertainti
commentari industrial/cycl channel highli encourag
manag call ta grow compani averag better
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
academic/govern acceler driven academ order
high-resolut mass spec system exposur nih small
sale result tend lumpi overal fund disburs
direct posit
exhibit growth driven comp-adjust acceler
industrial/appli government/academ
tax larg offset margin/buyback chang maintain pt overal
maintain organ growth forecast rais forecast
account stronger oper environ trend
busi line rais ebit margin model organ
increment margin larg consist averag trend
overal model organ margin expans
manag guid gross margin flat
awar target cost cut program sg net tax chang
higher buy-back assumpt rais ep estim
maintain pt use target yield maintain ew
rate see favor margin expansion/fre cash flow growth stori
tool
thomson reuter morgan stanley research
bull case ep
bull case ep
competit posit macro stronger expect lead
sustain top-line growth ebit margin expans cost
program price robust anticip pharma momentum
remain stronger longer expect gain market share
industrial/academ market drive upsid multipl expand
earn current peak level
base ep
base ep
pharma momentum drive organ growth share loss
moder acceler academic/industri market support top-
line margin expans remain flat cost program fail gener materi
save price power increas pt reflect yield
estim impli ep around current level pt
emb expect substanti capit deploy ep benefit
bear ep
bear ep
pharma academ growth challeng market share loss greater
expect lead top-line growth program fail gain
traction price come pressur lead ebit margin declin
multipl contract three-year histor averag
direct beneficiari
momentum pharma market tool
stronger share pharma market trend
support case stronger top line growth
opportun still appear limit
compar peer think peer
averag organ margin
expans next two year vs
closer see upsid
estim robust oper
improv initi
knowledg dollar amount expect
save program given
modest margin expans outlook expect
ep growth remain modest rel
peer vs coverag
median
china exposur concentr pharma
market remain strong
risk achiev price
market deceler tough comp
posit less defens expect
share loss increas iii oper
leverag weaker expect cost
program fail gain traction price
market acceler stronger
budget ii competit posit
defens expect iii oper
leverag higher expect
robust cost program price power
combin recur revenu servic chemistri consum y/i
y/i strong growth discoveri thermal analyz
organ strong us china
organ tough comp broad base strength
us y/i broad base browth pickup spend mid-size/larg pharma
asia led china india rebound gst japan steadi
exhibit estim organ growth
accel sale
overal similar stabl industrial/appli deceler academic/pharma
channel improv given us/eu budget acceler deceler tough comp
survey suggest budget acceler deceler tough comp
stabl msd growth driven continu strength cyclic indic
acquisit sell day
acquisit sell day
exhibit chang forecast
sale
sale
sale
sale
sale
sale
guidanc
hope stabl
sale growth
sale growth
increas
increas
guidanc
million except ep
acq sell day
compani data morgan stanley research
approv brazil
valuat risk
thomson reuter morgan stanley research
thomson reuter morgan stanley research
thomson reuter morgan stanley research
thomson reuter morgan stanley research
price target base yield estim
base upon organ growth ebit margin expans impli
ep multipl direct beneficiari momentum
pharma market tool yet see cours compani grow ep faster
larg cap peer group compani optim oper focu pharma
driver compani reason compani unlik
abl maintain multipl time despit superior product line-up
downsid risk includ pharma end-market deceler tough comp fade
replac cycl ii competit posit less defens expect share loss
increas iii oper leverag weaker expect cost program fail gain
traction price power moder upsid risk includ pharma end-market
acceler stronger budget ii competit posit defens
expect iii oper leverag higher expect robust cost
program price power
total good sold
total chemisti consum
